Inventiva s.a.IVA.US Overview
IVA Overall Performance
IVA AI Analysis & Strategy
IVA Recent Performance
2.56%
Inventiva s.a.
0.81%
Avg of Sector
-1.14%
S&P500
IVA PowerScanner
IVA Key Information
IVA Valuation Metrics
IVA Earnings Table
IVA Profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.